A critical role of protein damage response in mediating cancer drug resistance

Chuxia Deng

DOI: https://doi.org/10.1101/2024.07.17.603840

2024-07-19

Abstract:Multidrug resistance (MDR) frequently occurs during cancer therapy and remains a major obstacle for the cure of most cancers. Drug resistance could exist intrinsically or be acquired by drug treatment, yet factors that regulate the resistance remain elusive. Here, we show that most anticancer drugs damage neosynthesized proteins prior to reaching their canonic targets and elicit profound cytotoxicity, which is largely compensated by protein damage response (PDR). We demonstrate that the PDR includes damage recognition and clearance that are mainly mediated by ubiquitin and proteasome systems, although some other factors, including cellular ATP levels and proliferation status, are also involved. We show that cancer stem cells (CSCs), which have lower protein synthesis, and drug resistance acquired cells (DRAC), which have higher proteasome activity, are more resistant than other cells. We further demonstrate that ATP promotes protein synthesis and suppresses proteasome activity, thus, increasing ATP production by PDK1 inhibition and using proteasome inhibitor to block protein damage clearance render CSCs and DRACs more vulnerable to anticancer drugs. Thus, patients with drug-resistant cancers and treatment-naive patients with low ATP levels and/or high proteasome activity can be identified and subtyped, and therapies containing PDK1-i and/or proteasome-i may be effective options for these patients.

Cancer Biology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is multidrug resistance (MDR) in cancer treatment. Specifically, the research focuses on how antitumor drugs damage newly synthesized proteins before reaching their classical targets, and how this protein damage response (PDR) affects the tolerance of cancer cells to drugs. The study found that most anticancer drugs can quickly cause damage to newly synthesized proteins after contacting cells, and this damage is recognized and removed through the ubiquitin - proteasome system. However, cancer cells with higher proteasome activity or lower ATP levels can more effectively remove damaged proteins, thereby acquiring resistance to multiple anticancer drugs.

### Summary of the main problems in the paper:
1. **Mechanism of multidrug resistance**: The research explored why many cancer cells gradually lose their sensitivity to anticancer drugs during treatment, especially when the drugs show good efficacy in the early stage of treatment.
2. **Role of protein damage response**: The research revealed the importance of protein damage response in the process of anticancer drugs, especially how the damage of newly synthesized proteins triggers intracellular repair mechanisms.
3. **Molecular basis of cancer cell resistance**: The research found that cancer cells acquire resistance to multiple drugs by enhancing proteasome activity to remove damaged proteins.
4. **Potential treatment strategies**: The research proposed possible methods to overcome cancer cell resistance by inhibiting proteasome activity or increasing ATP levels.

### Key findings:
- **Most anticancer drugs can quickly damage newly synthesized proteins after contacting cells**, which may be one of their main toxicity mechanisms.
- **Protein damage response includes damage recognition and removal**, mainly mediated by the ubiquitin - proteasome system.
- **Cancer stem cells (CSCs) and acquired resistant cells (DRACs)** are more tolerant to drugs due to their lower protein synthesis rate and higher proteasome activity.
- **ATP plays a key role in regulating protein damage response**. By inhibiting PDK1 to increase mitochondrial ATP production and using proteasome inhibitors can increase the sensitivity of these cells to anticancer drugs.

### Potential applications:
- **Patient classification**: By detecting the ATP levels and proteasome activity of patients, it is possible to identify patient groups that may be more effective for specific treatment regimens.
- **Combined treatment**: Combining PDK1 inhibitors and proteasome inhibitors may become an effective strategy for treating multidrug - resistant cancers.

These findings not only enhance the understanding of the mechanism of multidrug resistance but also provide a theoretical basis for the development of new treatment strategies.